BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20(11): 2955-2961 [PMID: 24659886 DOI: 10.3748/wjg.v20.i11.2955]
URL: https://www.wjgnet.com/1948-5182/full/v20/i11/2955.htm
Number Citing Articles
1
Tomomi Kogiso, Katsutoshi Tokushige. Key roles of hepatologists in successful liver transplantationHepatology Research 2018; 48(8): 608 doi: 10.1111/hepr.13183
2
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 updateHepatology Research 2020; 50(8): 892 doi: 10.1111/hepr.13504
3
Ming-Lun Yeh, Ming-Yen Hsieh, Ching-I Huang, Chung-Feng Huang, Meng-Hsuan Hsieh, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infectionJournal of Gastroenterology and Hepatology 2016; 31(4): 835 doi: 10.1111/jgh.13203
4
Philippe Gallay, Daren Ure, Michael Bobardt, Udayan Chatterji, James Ou, Daniel Trepanier, Robert Foster, Haitao Guo. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic micePLOS ONE 2019; 14(6): e0217433 doi: 10.1371/journal.pone.0217433
5
Kazuhiro Murai, Hayato Hikita, Yugo Kai, Yasuteru Kondo, Makoto Fukuoka, Keisuke Fukutomi, Akira Doi, Takuo Yamai, Tasuku Nakabori, Ryo Fukuda, Takeshi Takahashi, Kei Miyakawa, Hiroshi Suemizu, Akihide Ryo, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara. Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathwayScientific Reports 2020; 10(1) doi: 10.1038/s41598-020-57603-9
6
Satomi Shimura, Koichi Watashi, Kento Fukano, Michael Peel, Ann Sluder, Fumihiro Kawai, Masashi Iwamoto, Senko Tsukuda, Junko S. Takeuchi, Takeshi Miyake, Masaya Sugiyama, Yuki Ogasawara, Sam-Yong Park, Yasuhito Tanaka, Hiroyuki Kusuhara, Masashi Mizokami, Camille Sureau, Takaji Wakita. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activityJournal of Hepatology 2017; 66(4): 685 doi: 10.1016/j.jhep.2016.11.009
7
Alberto Frosi, Maria Franca Meloni, Giacomo Frosi. Cluster of hepatitis C in a family: a twenty-year follow-upCentral European Journal of Public Health 2019; 27(2): 170 doi: 10.21101/cejph.a5027
8
Senko Tsukuda, Koichi Watashi, Taichi Hojima, Masanori Isogawa, Masashi Iwamoto, Katsumi Omagari, Ryosuke Suzuki, Hideki Aizaki, Soichi Kojima, Masaya Sugiyama, Akiko Saito, Yasuhito Tanaka, Masashi Mizokami, Camille Sureau, Takaji Wakita. A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteinsHepatology 2017; 65(4): 1104 doi: 10.1002/hep.28952
9
S. K. Sarin, M. Kumar, G. K. Lau, Z. Abbas, H. L. Y. Chan, C. J. Chen, D. S. Chen, H. L. Chen, P. J. Chen, R. N. Chien, A. K. Dokmeci, Ed Gane, J. L. Hou, W. Jafri, J. Jia, J. H. Kim, C. L. Lai, H. C. Lee, S. G. Lim, C. J. Liu, S. Locarnini, M. Al Mahtab, R. Mohamed, M. Omata, J. Park, T. Piratvisuth, B. C. Sharma, J. Sollano, F. S. Wang, L. Wei, M. F. Yuen, S. S. Zheng, J. H. Kao. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatology International 2016; 10(1): 1 doi: 10.1007/s12072-015-9675-4
10
Andrea Martins Melo Fontenele, Juliana Braga Furtado Gainer, Daniel Viana da Silva e Silva, Max Diego Cruz Santos, João Victor Salgado, Natalino Salgado Filho, Adalgisa Sousa Paiva Ferreira. Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast BrazilHemodialysis International 2015; 19(3): 353 doi: 10.1111/hdi.12285
11
Sunil S. Solomon, Aylur K. Srikrishnan, Allison M. McFall, M. Suresh Kumar, Shanmugam Saravanan, Pachamuthu Balakrishnan, Suniti Solomon, David L. Thomas, Mark S. Sulkowski, Shruti H. Mehta, Anand S Mehta. Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, IndiaPLOS ONE 2016; 11(1): e0147879 doi: 10.1371/journal.pone.0147879
12
Masashi Iwamoto, Koichi Watashi. Closing the door on hepatitis B and D virus entry: what are our therapeutic options?Future Virology 2016; 11(11): 715 doi: 10.2217/fvl-2016-0097
13
Qin Ning, Ting Wu, Hai-Bin Su, Ke Ma, Jun-Ying Qi, Ming Ni, Di Wu. Acute Exacerbation of Chronic Hepatitis B2019; : 371 doi: 10.1007/978-94-024-1603-9_5
14
Heather L. Stevenson, Netanya S. Utay. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral eraTropical Diseases, Travel Medicine and Vaccines 2016; 2(1) doi: 10.1186/s40794-016-0038-5
15
Carla S. Coffin, Norah A. Terrault. Hepatitis B Virus and Liver Disease2018; : 239 doi: 10.1007/978-981-10-4843-2_13
16
Lee-Won Chong, Chih-Chao Hsu, Chang-Yin Lee, Ruey-Hwang Chou, Cheng-Li Lin, Kuang-Hsi Chang, Yi-Chao Hsu. Association of viral hepatitis and bipolar disorder: a nationwide population-based studyJournal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1542-3
17
Kimberly A. Toussaint-Miller, Jennifer Andres. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 InfectionAnnals of Pharmacotherapy 2015; 49(9): 1015 doi: 10.1177/1060028015592015
18
Jamil A. Al-Mughales. Co-infection assessment in HBV, HCV, and HIV patients in Western Saudi ArabiaJournal of Medical Virology 2016; 88(9): 1545 doi: 10.1002/jmv.24503